M. Lievens

发表

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.

Kwaku Poku Asante, M. Tanner, K. Marsh, 2012, The New England journal of medicine.

Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children.

Juliana K. Wambua, K. Marsh, A. Olotu, 2016, The New England journal of medicine.

Host-mediated selection impacts the diversity of Plasmodium falciparum antigens within infections

Kwaku Poku Asante, D. Wirth, S. Adjei, 2018, Nature Communications.

Within-infection diversity of Plasmodium falciparum antigens reflects host-mediated selection

D. Wirth, S. Volkman, D. Neafsey, 2017, bioRxiv.

Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area

Conor P. Cahill, M. Demoitié, L. Otieno, 2009, PloS one.

Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial.

Q. Bassat, J. Sacarlal, P. Aide, 2008, Vaccine.

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.

M. Demoitié, K. Marsh, C. Drakeley, 2008, The New England journal of medicine.

Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01E and Protection against P falciparum Clinical Malaria

K. Marsh, A. Olotu, P. Bejon, 2011, PloS one.

Hepatitis A vaccine: Indirect evidence of immune memory 12 years after the primary course

P. van Damme, M. Lievens, K. Van Herck, 2004, Journal of medical virology.

Immunogenicity of Twinrix™ in older adults: a critical analysis

M. Lievens, I. Dieussaert, F. André, 2003, Expert review of vaccines.

Safety, Immunogenicity and Duration of Protection of the RTS,S/AS02D Malaria Vaccine: One Year Follow-Up of a Randomized Controlled Phase I/IIb Trial

Q. Bassat, J. Sacarlal, P. Aide, 2010, PloS one.

Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children

Kwaku Poku Asante, M. Demoitié, S. Owusu-Agyei, 2009, PloS one.

Insights into Long-Lasting Protection Induced by RTS,S/AS02A Malaria Vaccine: Further Results from a Phase IIb Trial in Mozambican Children

Q. Bassat, J. Sacarlal, P. Aide, 2009, PloS one.

Induction of Plasmodium falciparum-Specific CD4+ T Cells and Memory B Cells in Gabonese Children Vaccinated with RTS,S/AS01E and RTS,S/AS02D

M. Demoitié, S. Agnandji, B. Lell, 2011, PloS one.

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP

R. Sinden, G. Cooke, M. Lievens, 2018, npj Vaccines.

RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype

M. Lievens, J. Vekemans, C. Ockenhouse, 2018, Vaccine.

Impact of RTS,S/AS02A and RTS,S/AS01B on Genotypes of P. falciparum in Adults Participating in a Malaria Vaccine Clinical Trial

Joe D. Cohen, A. Leach, M. Lievens, 2009, PloS one.

Phase Ii, Randomized Trial to Assess the Safety and Immunogenicity of the Candidate Malaria Vaccines Rts,S/As02 and Rts,S/As01 When Given According to Different Vaccination Schedules in Children in Ghana

Kwaku Poku Asante, M. Demoitié, S. Owusu-Agyei, 2008 .

Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine.

Trevor Bedford, Kevin Marsh, Elizabeth M. Ryan, 2015, The New England journal of medicine.

Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.

Q. Bassat, M. Demoitié, J. Sacarlal, 2011, Vaccine.

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.

Pedro Alonso, Trudie Lang, Bernhards Ogutu, 2011, The New England journal of medicine.

A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults

Linda A. Murray, N. Waters, E. Jongert, 2020, The Journal of infectious diseases.

Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.

Paige E. Waterman, N. Waters, W. Robinson, 2016, The Journal of infectious diseases.

Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial

Conor P. Cahill, J. Sacarlal, J. Aponte, 2007, Trials.

Five year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia

K. Bojang, Joe D. Cohen, A. Leach, 2009, Human vaccines.

A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01E in a controlled human malaria infection challenge.

M. Lievens, O. Ofori-Anyinam, M. Debois, 2021, Vaccine.

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

Q. Bassat, M. Demoitié, J. Sacarlal, 2007, The Lancet.

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

Q. Bassat, C. Menéndez, J. Sacarlal, 2005, The Lancet.

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP

R. Sinden, G. Cooke, M. Lievens, 2016, Journal of Infectious Diseases.

Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial.

H. Tinto, H. Sorgho, I. Valéa, 2019, The Lancet. Infectious diseases.

Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients.

M. Lievens, J. Bayas, J. Beran, 2005, Kidney international.

Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01E malaria vaccine in African children: a randomized trial

O. Traoré, S. Adjei, H. Tinto, 2020, Human Vaccines & Immunotherapeutics.

Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial.

M. Hamel, S. Kariuki, M. Oneko, 2016, The Lancet. Infectious diseases.

Development and Technical and Clinical Validation of a Quantitative Enzyme-Linked Immunosorbent Assay for the Detection of Human Antibodies to Hepatitis B Surface Antigen in Recipients of Recombinant Hepatitis B Virus Vaccine

M. Lievens, J. Jacquet, B. Hoet, 2009, Clinical and Vaccine Immunology.

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP

R. Sinden, G. Cooke, M. Lievens, 2018, npj Vaccines.

Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04.

M. Lievens, B. Genton, J. Zuckerman, 2004, Vaccine.

Malaria Treatment with Atovaquone-Proguanil in Malaria-Immune Adults: Implications for Malaria Intervention Trials and for Pre-Exposure Prophylaxis of Malaria

B. Ogutu, W. Ballou, M. Lievens, 2008, Antimicrobial Agents and Chemotherapy.

Virological Examinations of Patients with AIDS‐Related Complex/Walter‐Reed 5 Enrolled in a Double‐Blind Placebo‐Controlled Study with Intravenous Gammaglobulin Administration.

M. Lievens, T. Mertens, A. Ramon, 1990, Vox sanguinis.

Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.

Kwaku Poku Asante, M. Tanner, S. Agnandji, 2011, The Lancet. Infectious diseases.

The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants

Kwaku Poku Asante, M. Tanner, S. Agnandji, 2015, Malaria Journal.

Serological Evidence of Discrete Spatial Clusters of Plasmodium falciparum Parasites

K. Marsh, T. Theander, C. Drakeley, 2011, PloS one.

Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa

Conor P. Cahill, E. Macete, S. Abdulla, 2011, Malaria Journal.

Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure.

Kevin Marsh, Juliana K. Wambua, Philip Bejon, 2013, The New England journal of medicine.

Phase Iib, Randomized, Double-Blind Trial to Assess the Efficacy, Safety and Immunogenicity of the Candidate Malaria Vaccine Rts,S/As01 in Kenyan and Tanzanian Children

M. Demoitié, K. Marsh, C. Drakeley, 2008 .

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.

V. A. Stewart, W. Ballou, Joe D. Cohen, 2009, The Journal of infectious diseases.

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.

M. Tanner, H. Mshinda, M. Demoitié, 2008, The New England journal of medicine.

Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults

W. Ballou, Joe D. Cohen, E. Jongert, 2015, PloS one.

Effect of the Pre-erythrocytic Candidate Malaria Vaccine RTS,S/AS01E on Blood Stage Immunity in Young Children

K. Marsh, C. Drakeley, A. Olotu, 2011, The Journal of infectious diseases.

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial

K. Marsh, C. Drakeley, A. Olotu, 2011, The Lancet. Infectious diseases.

Malaria Intervention Trials and for Pre-Exposure Prophylaxis of Malaria 3 4 Authors: 5

B. Ogutu, M. Lievens, J. Waitumbi, 2008 .

Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa

Kwaku Poku Asante, M. Tanner, S. Adjei, 2019, Vaccine.

Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial

O. Traoré, S. Adjei, H. Tinto, 2018, Human vaccines & immunotherapeutics.

Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization.

Kwaku Poku Asante, M. Tanner, M. Demoitié, 2010, The Journal of infectious diseases.

Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5–17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial

S. Adjei, M. Oneko, K. Otieno, 2022, The Lancet. Infectious diseases.

RTS,S/AS02A Malaria Vaccine Does Not Induce Parasite CSP T Cell Epitope Selection and Reduces Multiplicity of Infection

D. Conway, J. Sacarlal, J. Aponte, 2006, PLoS clinical trials.

Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa

Kwaku Poku Asante, M. Tanner, S. Adjei, 2019, Human vaccines & immunotherapeutics.

Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02D malaria vaccine in infants living in a malaria-endemic region

M. Tanner, H. Mshinda, S. Abdulla, 2013, Malaria Journal.

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B with ChAd-MVA Vectored Vaccines Expressing ME-TRAP

R. Sinden, G. Cooke, M. Lievens, 2016 .

Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi

J. Bailey, I. Hoffman, T. Mvalo, 2020, BMC Public Health.

T Cell Responses to the RTS,S/AS01E and RTS,S/AS02D Malaria Candidate Vaccines Administered According to Different Schedules to Ghanaian Children

Kwaku Poku Asante, S. Owusu-Agyei, D. Dosoo, 2011, PloS one.

Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children.

Inácio Mandomando, Marie-Claude Dubois, Quique Bassat, 2009, The Journal of infectious diseases.

Immunogenicity and safety of the candidate RTS,S/AS01 vaccine in young Nigerian children: a randomized, double-blind, lot-to-lot consistency trial.

E. Jongert, A. Leach, M. Lievens, 2014, Vaccine.

RTS,S/AS01 Malaria Vaccine Efficacy is Not Modified by Seasonal Precipitation: Results from a Phase 3 Randomized Controlled Trial in Malawi

M. Hudgens, F. Martinson, I. Hoffman, 2017, Scientific Reports.

Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS , S / AS 01 malaria vaccine in African children

J. Aponte, P. Bejon, A. Leach, 2011 .

Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial.

Kwaku Poku Asante, S. Adjei, S. Owusu-Agyei, 2020, Vaccine.

RTS,S/AS01 Malaria Vaccine Efficacy is Not Modified by Seasonal Precipitation: Results from a Phase 3 Randomized Controlled Trial in Malawi

M. Hudgens, F. Martinson, M. Lievens, 2017, Scientific Reports.

Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines

Joe D. Cohen, E. Jongert, M. Lievens, 2014, Human vaccines & immunotherapeutics.

Safety of the Malaria Vaccine Candidate, RTS,S/AS01E in 5 to 17 Month Old Kenyan and Tanzanian Children

K. Marsh, C. Drakeley, A. Olotu, 2010, PloS one.

A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon

M. Demoitié, S. Agnandji, B. Lell, 2009, PloS one.

Pooled analysis of safety data from pediatric Phase II RTS,S/AS malaria candidate vaccine trials

Yolanda Guerra, D. Lapierre, A. Leach, 2011, Human vaccines.

Host-mediated selection impacts the diversity of Plasmodium falciparum antigens within infections

Kwaku Poku Asante, D. Wirth, S. Volkman, 2018, Nature Communications.

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.

M. Demoitié, K. Marsh, A. Olotu, 2008, The New England journal of medicine.

119. Safety and Reactogenicity of an Investigational Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine for Adults ≥ 60 Years of Age (RSVPreF3 OA): an Interim Analysis at 6 Months after Vaccination

Shinn-Jang Hwang, M. Lievens, C. Liu, 2022, Open Forum Infectious Diseases.

96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination

Shinn-Jang Hwang, M. Lievens, C. Liu, 2022, Open Forum Infectious Diseases.

Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS,S/AS01 malaria vaccine in African children

J. Aponte, P. Bejon, M. Lievens, 2011, Malaria Journal.

Immunogenicity and safety of the candidate RTS,S/AS01 vaccine in young Nigerian children: a randomized, double-blind, lot-to-lot consistency trial.

E. Jongert, A. Leach, M. Lievens, 2014, Vaccine.

Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults

W. Ballou, E. Jongert, M. Lievens, 2015, PloS one.